Earnings Release • Feb 26, 2025
Earnings Release
Open in ViewerOpens in native device viewer
The LISI Board of Directors, meeting under the chairmanship of Mr. Jean-Philippe KOHLER on February 26, 2025, reviewed the final audited accounts for the financial year ended December 31, 2024. They will be submitted for approval to the Ordinary General Meeting on April 25, 2025.
| 12 months ending December 31, | 2024 | 2023 | Changes | ||||
|---|---|---|---|---|---|---|---|
| Key components of the income statement | |||||||
| Sales | €M | 1,794.0 | 1,630.4 | + 10.0% | |||
| EBITDA | €M | 211.8 | 178.2 | + 18.9% | |||
| EBITDA margin | % | 11.8 | 10.9 | + 0.9 pt | |||
| EBIT | €M | 115.0 | 90.7 | + 26.9% | |||
| Current operating margin | % | 6.4 | 5.6 | + 0.8 pt | |||
| Net profit | €M | 56.0 | 37.5 | + 49.2% | |||
| Net earnings per share | € | 1.23 | 0.83 | + 48.2% | |||
| Operating cash flow | €M | 170.0 | 132.5 | + €37.5 M | |||
| Net industrial CAPEX | €M | - 100.4 | - 96.7 | + €3.7 M | |||
| Operating free cash flow* | €M | 57.7 | 22.2 | + €35.5 M | |||
| Net debt | €M | 488.5 | 501.1 | - €12.6 M | |||
| Net debt-to-equity ratio | % | 48.6 | 53.4 | - 4.8 pts |
8 * Free Operating Cash Flow: net operating cash flow minus net CAPEX and changes in working capital requirements
Consolidated revenue for 2024 reaches a record level of €1,794.0 M, up + 10.0% on 2023.
In line with the objective of maintaining positive organic growth in 2024, the increase in revenue adjusted for currency fluctuations and excluding scope effects stands at + 10.2% for the full year.
| Q1 | Q2 | Q3 | Q4 | Total | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2023 | 2024 | 2023 | 2024 | 2023 | 2024 | 2023 | 2024 | 2023 | 2024 | |
| LISI AEROSPACE | 199,8 | 252,5 | 214,7 | 252,5 | 200,2 | 237,1 | 224,2 | 287,9 | 838,9 | 1 030,1 |
| LISI AUTOMOTIVE | 159,1 | 157,3 | 159,4 | 153,3 | 150,2 | 136,6 | 141,7 | 132,5 | 610,4 | 579,7 |
| LISI MEDICAL | 42,6 | 39,7 | 46,5 | 48,8 | 46,0 | 45,9 | 46,8 | 51,0 | 181,9 | 185,3 |
| LISI Consolidé | 401,3 | 449,3 | 420,4 | 454,3 | 396,2 | 419,4 | 412,5 | 471,1 | 1 630,4 | 1 794,0 |
| Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Total 2023 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| ∆ | ∆ like for like* | ∆ | ∆ like for like* | ∆ | ∆ like for like* | ∆ | ∆ like for like* | ∆ | ∆ like for like* | |
| LISI AEROSPACE | +26,4% | +27,0% | +17,6% | +17,2% | +18,5% | +18,7% | +28,4% | +28,0% | +22,8% | +22,8% |
| LISI AUTOMOTIVE | -1,2% | -0,6% | -3,9% | -3,7% | -9,1% | -8,2% | -6,5% | -6,7% | -5,0% | -4,7% |
| LISI MEDICAL | -6,9% | -6,7% | +4,8% | +4,4% | -0,2% | +0,8% | +8,9% | +7,6% | +1,8% | +1,7% |
| LISI Consolidé | +11,9% | +12,5% | +8,1% | +7,9% | +5,9% | +6,4% | +14,2% | +13,7% | +10,0% | +10,2% |
∆ like for like* = on a like-for-like and constant exchange rate basis
Adjusted for currency fluctuations and excluding scope effects, Q4 revenue increased by + 13.7% on the same period of the previous financial year. It benefits from the continued strong increases in production across all segments of the aeronautics market.
The LISI AEROSPACE division's annual revenue exceeds €1 Bn for the first time since 2017 and reaches €1,030.1 M, up + 22.8% on 2023.
Q4 2024 represents the twelfth consecutive quarter of double-digit growth and stands at €287.9 M (+ 28.4% on the same period of the previous financial year).
For the 2024 financial year, the "Fasteners" segment in Europe (+ 26.9%) will benefit the most from the ramp-ups of single-aisle aircraft and aeronautical activity in general. Its sales revenue has increased by more than 20.0% per year over the past three years. The "Fasteners" segment in North America also confirms a good trend (+ 25.5%).
The "Structural Components" segment has doubled its growth in two years, displaying an increase of + 16.0% in 2024 on 2023. The difficulties in sourcing raw materials and the problems of recruitment in certain employment areas are easing without disappearing completely.
Adjusted for currency effects and excluding scope effects, the LISI AEROSPACE division's revenue increased by + 28.0% in Q4, representing organic growth of + 22.8% for the whole of 2024.
The LISI AUTOMOTIVE division's annual revenue stands at €579.7 M, down - 5.0% on 2023. It is suffering from the effects of contractions in global production of its main customers (- 7.5% on 2023) which began at the end of Q2 2024 and worsened in the last months of the year (- 9.3% in H2). Against this backdrop, the division nevertheless maintains very good momentum in taking orders for new products, which amount to approximately €71.0 M over the whole of 2024, or 12.4% of sales revenue (€73.0 M in 2023). These orders are particularly well oriented in the "Clipped Solutions" segment in Europe and the United States and in the "Safety Mechanical Components" segment in the field of braking in particular. This reflects the portfolio's refocusing on products with higher added value undertaken by the LISI AUTOMOTIVE division for many years, as demonstrated by the planned sale of its French subsidiary LISI AUTOMOTIVE Nomel SAS. Specializing in the manufacture of nuts by cold heading and washers by vertical cutting, the company, which posted sales of €35.2 M in 2024, is slated to join the ZerobaseInvest GmbH group at the 28th of February 2025. The subsidiary's income statement was consolidated for the entire financial year 2024 and the balance sheet was treated as of December 31, 2024 as a non-current asset held for sale in accordance with IFRS 5.
Q4 2024 revenue stands at €132.5 M (- 6.5% on the same period of the previous financial year).
Adjusted for currency effects and excluding scope effects, the LISI AUTOMOTIVE division's revenue decreased by - 6.7% in Q4, representing a - 4.7% reduction for the whole of 2024.
The LISI MEDICAL division's revenue is up + 1.8% on 2023, after two years of increases of more than 20%, and stands at €185.3 M. Added to this high comparison base are difficulties obtaining supplies of raw materials which disrupted production throughout the year.
The sales growth momentum (+ 51.9% in three years) is driven by new products launched by the division, whether in orthopedic reconstruction or in the field of minimally invasive robotic surgery.
Adjusted for currency effects and excluding scope effects, the LISI MEDICAL division's revenue increased by + 7.6% in Q4, representing organic growth of + 1.7% for the whole of 2024.
The EBITDA margin reached 11.8%, a 0.9-point increase on 2023. In the LISI AEROSPACE division, it benefited from the improvement in industrial productivity thanks to the training efforts of the numerous recruits in 2023 and 2024. It also reflects the finalization of negotiations aimed at reflecting inflation in sales prices. Added to this is the work of adjusting fixed costs kicked off in the LISI AUTOMOTIVE division. All of these factors allow to display an EBITDA margin of 12.7% in Q4 2024.
Net provision reversals amount to €7.5 M (€13.4 M in 2023). These provision reversals do not improve the bottom line, they are linked to some operating expenses for the period.
The current operating margin increased by + 0.8 point to 6.4%.
Non-recurring operating income and expenses, which amount to - €23.1 M (- €4.3 M in 2023), consist mainly of costs linked to the industrial reorganizations of the LISI AUTOMOTIVE division.
The financial loss stands at - €15.9 M (- €25.6 M in 2023); this is mainly due to the following factors:
Net financial expenses compared to debt excluding IFRS 16 represent 5.8% (4.1% in 2023).
The tax expense, calculated on the basis of the corporate tax and compared to net profit before tax, reflects an average effective tax rate of 26.1%, close to that of 2023 (25.9%).
Consequently, the group share of net profit increased by + 49.2% and stood at €56.0 M (i.e. 3.1% of sales), compared to €37.5 M (2.3% of sales) in 2023. Earnings per share stood at €1.23 (+ 48.2%).
The financial balances remain robust with operational cash flow at €170.0 M (9.5% of sales) which finances, in compliance with the criteria set by the global CSR plan, slightly higher CAPEX of €100.4 M (5.6% of sales).
LISI AEROSPACE invested €54.4 M in 2024 to increase its production capacity in order to support the ramp-up of its customers and continue the modernization of its equipment, in particular with:
Actions to improve performance and modernize production resources were continued, particularly in the LISI AUTOMOTIVE division (€29.4 M of capex).
Examples include:
CAPEX also remained high for LISI MEDICAL (€16.6 M) and focused on the extension of the Big Lake plant to cope with future growth and on increasing production capacities for new products such as:
The level of working capital requirements is down in number of days for the third consecutive year despite the increase in work-in-progress inventories and the maintenance of strategic inventories of raw materials to meet uncertain supply times and secure the long-term increase in production levels in the LISI AEROSPACE division. It stands at 72 days of sales (75 days in 2023) with inventories in number of days of sales also falling (103 days in 2024 compared to 105 days in 2023).
Taking these aspects into account and in accordance with the objectives, the operating Free Cash Flow is definitely positive and stands at €57.7 M (3.2% of sales).
Net debt stands at €488.5 M and includes €185.0 M in financing linked to the 2023 Public Share Buyback Offer and €111.0 M in debt relating to IFRS 16. It is down by €12.6 M and represents 48.6% of equity (53.4% as of December 31, 2023). Compared to EBITDA, the net debt ratio stands at 2.3x (2.8x as of December 31, 2023), well below the covenant authorized by the banking partners (3.5x).
The return on capital employed before taxes stands at 7.7%, an improvement compared to that of 2023 (6.3%).
The annual impairment tests have not revealed any loss of value.
The Board of Directors will propose for approval by the Ordinary General Meeting of shareholders to set the dividend at €0.39 per share for the 2024 financial year (€0.31 in 2023).
| In €M | 2024 | 2023 | Changes |
|---|---|---|---|
| Sales | 1,030.1 | 838.9 | + 22.8% |
| EBITDA | 135.3 | 95.8 | + 41.3% |
| EBIT | 85.7 | 50.2 | + 70.7% |
| Operating cash flow | 91.6 | 66.5 | + 37.7% |
| Net industrial CAPEX | - 54.4 | - 51.0 | + 6.7% |
| Free Cash Flow | 20.8 | 7.0 | + €13.8 M |
| Employed at the end of the year | 6,279 | 5,871 | + 6.9% |
| Average full-time equivalent workforce | 6,755 | 6,231 | + 8.4% |
| In €M | 2024 | 2023 | Changes |
|---|---|---|---|
| Sales | 579.7 | 610.4 | - 5.0% |
| EBITDA | 51.4 | 52.1 | - 1.3% |
| EBIT | 17.2 | 21.7 | - 20.9% |
| Operating cash flow | 39.3 | 39.1 | + 0.4% |
| Net industrial CAPEX | - 29.4 | - 28.5 | + 3.2% |
| Free Cash Flow | 9.6 | 25.9 | - €16.3 M |
| Employed at the end of the year | 3,076 | 3,202 | - 3.9% |
| Average full-time equivalent workforce | 3,183 | 3,292 | - 3.3% |
| In €M | 2024 | 2023 | Changes |
|---|---|---|---|
| Sales | 185.3 | 181.9 | + 1.8% |
| EBITDA | 28.2 | 31.6 | - 10.8% |
| EBIT | 16.3 | 20.8 | - 21.7% |
| Operating cash flow | 23.1 | 26.8 | - 13.8% |
| Net industrial CAPEX | - 16.6 | - 17.1 | - 2.9% |
| Free Cash Flow | 6.7 | 8.0 | - €1.3 M |
| Employed at the end of the year | 812 | 846 | - 4.0% |
| Average full-time equivalent workforce | 857 | 890 | - 3.7% |
The LISI Group is deploying a CSR strategy across all levels of the company. Since 2022, this approach has responded to the LISI Group's purpose: "shape and share sustainable links". It is thus structured around the 3Ps - People, Planet, Profit - and the three programs of the LISI System: LEAP (LISI Excellence Achievement Program), E-HSE, COS (Controlling Operating System).
In 2024, the Group made significant progress in sustainability under the theme of "Acting with impact".
In line with the Corporate Sustainability Reporting Directive (CSRD), the sustainability report now includes an in-depth analysis of double materiality and a precise assessment of gaps on key data points. The Group is thus prepared to anticipate and respond to new regulatory expectations.
Demand is still strong in civil aeronautics and particularly in the Airbus ecosystem. It benefits from the dynamism of the maintenance market linked to the high level of traffic in the commercial aircraft fleet and a book-to-bill ratio (order / sales values) which remains significantly higher than 1. All other market segments - apart from Boeing - including helicopters and the military (15% of LISI AEROSPACE's sales), are also very dynamic and well-oriented over the long term.
The LISI AEROSPACE division is therefore approaching the 2025 financial year with strong visibility on its order books. It will benefit from a revised sales price base after the finalization in 2024 of the last negotiations aimed at reflecting the effects of inflation in sales prices.
The points of attention will focus on:
The slowdown in activity observed by the LISI AUTOMOTIVE division among its main customers is expected to continue during H1 of the 2025 financial year in a market experiencing profound technological and geographical changes.
The division has many assets that will enable it to adapt and continue to develop despite an uncertain environment. Examples include:
The long-term growth outlook for minimally invasive robotic surgery and orthopedic reconstruction remains positive. The division enjoys consistently strong order books. Priority will be given to the continued development of new products and the increase of production volumes by relying on the Big Lake site (United States), the extension of which has been completed. The resolution of operational difficulties linked to material supply problems should provide support for the improvement of margins.
The aeronautical development plan will drive the Group's growth with excellent long-term visibility. Medium-term uncertainties related to the evolution of the global automobile market or, in the shorter term, to the consequences of the strike in H2 2024 at Boeing in the United States could weigh on the dynamics of improving LISI's performance.
The Group carefully monitors the application of customs duties, not only upon entry into the United States, but also in other geographies where it operates. At this stage, the vast majority of activity would not be affected, but it could be penalized if certain exemption systems previously in force were to disappear.
In an environment where inflationary pressures are dwindling and assuming a constant exchange rate and a limited impact of customs duties implemented by the United States, the Group aims to improve its benchmark financial indicators for the third consecutive financial year, including EBIT, and to resume generating positive Free Cash Flow.
(in thousands of euros)
| 12/31/2024 | 12/31/2023 | |
|---|---|---|
| REVENUE EXCL. TAX | 1 794 050 | 1 630 444 |
| Changes in inventories, finished products and production in progress | 19 796 | 19 400 |
| Total production | 1 813 846 | 1 649 844 |
| Other income | 60 778 | 47 901 |
| TOTAL OPERATING REVENUES | 1 874 624 | 1 697 745 |
| Consumed goods | (549 169) | (513 070) |
| Other purchases and external expenses | (424 353) | (385 508) |
| Taxes and duties | (10 848) | (9 509) |
| employee benefits expense (including temps) | (678 425) | (611 461) |
| EBITDA | 211 829 | 178 197 |
| Depreciation | (104 250) | (100 903) |
| Net provisions | 7 455 | 13 389 |
| CURRENT OPERATING PROFIT (EBIT) | 115 034 | 90 683 |
| Non-recurring operating income and expenses | (23 094) | (4 312) |
| OPERATING PROFIT | 91 940 | 86 371 |
| Financing expenses and revenue on cash | (26 784) | (20 206) |
| Revenue on cash | 4 557 | 1 652 |
| Financing expenses | (31 341) | (21 858) |
| Other financial income and expenses | 10 883 | (5 415) |
| Other financial items | 35 066 | 18 329 |
| Other interest expenses | (24 183) | (23 744) |
| Taxes (including CVAE (Tax on Companies' Added Value)) | (20 615) | (24 083) |
| PROFIT (LOSS) FOR THE PERIOD | 55 424 | 36 667 |
| Attributable as company shareholders' equity | 56 006 | 37 533 |
| Interest not granting control over the company | (582) | (866) |
| EARNINGS PER SHARE (IN €) | 1,23 | 0,83 |
| DILUTED EARNINGS PER SHARE (IN €) | 1,20 | 0,81 |
(in thousands of euros)
| 12/31/2024 | 12/31/2023 | |
|---|---|---|
| PROFIT (LOSS) FOR THE PERIOD | 55 424 | 36 667 |
| Elements not recyclable in result | ||
| Revaluation of net liabilities (assets) of defined benefit plans (gross element) | 2 132 | -4 887 |
| Revaluation of net liabilities (assets) of defined benefit plans (tax impact) | -761 | 781 |
| Elements that can subsequently be recycled as a result | ||
| Exchange rate differences resulting from foreign operations | 23 873 | -7 993 |
| Hedging instruments (gross element) | -1 713 | 1 812 |
| Hedging instruments (tax impact) | 598 | -656 |
| TOTAL OTHER PORTIONS OF GLOBAL EARNINGS FOR THE PERIOD, AFTER TAXES | 24 129 | -10 943 |
| TOTAL OVERALL INCOME FOR THE PERIOD | 79 552 | 25 723 |
| Attributable as company shareholders' equity | 42 222 | 26 425 |
| Interest not granting control over the company | -267 | -701 |
| ASSETS (in thousands of euros) | 12/31/2024 | 12/31/2023 |
|---|---|---|
| NON-CURRENT ASSETS | ||
| Goodwill | 419 379 | 406 722 |
| Other intangible assets | 29 693 | 28 682 |
| Tangible assets | 765 416 | 746 880 |
| Non-current financial assets | 21 501 | 15 120 |
| Deferred tax assets | 44 913 | 44 193 |
| Other non-current assets | 123 | 85 |
| TOTAL NON-CURRENT ASSETS | 1 281 025 | 1 241 682 |
| CURRENT ASSETS | ||
| Inventories | 468 174 | 437 323 |
| Taxes - Claim on the state | 12 360 | 14 112 |
| Trade and other receivables | 244 995 | 226 137 |
| Cash and cash equivalents | 191 660 | 139 312 |
| TOTAL CURRENT ASSETS | 917 190 | 816 884 |
| Assets held for sale | 12 068 | – |
| TOTAL ASSETS | 2 210 283 | 2 058 566 |
| TOTAL EQUITY AND LIABILITIES (in thousands of euros) | 12/31/2024 | 12/31/2023 |
|---|---|---|
| SHAREHOLDERS' EQUITY | ||
| Capital stock | 18 615 | 18 615 |
| Additional paid-in-capital | – | – |
| Treasury shares | (20 080) | (19 638) |
| Consolidated reserves | 891 754 | 866 704 |
| Conversion reserves | 59 635 | 35 908 |
| Other elements of comprehensive income | (6 295) | (6 554) |
| Profit (loss) for the period | 56 006 | 37 533 |
| TOTAL SHAREHOLDERS' EQUITY - GROUP'S SHARE | 999 633 | 932 565 |
| Interest not granting control over the company | 6 567 | 6 171 |
| TOTAL SHAREHOLDERS' EQUITY | 1 006 200 | 938 736 |
| NON-CURRENT LIABILITIES | ||
| Non-current provisions | 48 627 | 52 859 |
| Non-current borrowings | 547 121 | 494 383 |
| Other non-currents liabilities | 14 979 | 10 792 |
| Deferred tax liaibilities | 47 973 | 48 897 |
| TOTAL NON-CURRENT LIABILITIES | 658 700 | 606 931 |
| CURRENT LIABILITIES | ||
| Current provisions | 15 327 | 10 054 |
| Current borrowings | 133 070 | 145 989 |
| Trade and other accounts payable | 378 591 | 356 027 |
| Taxes due | 5 535 | 829 |
| TOTAL CURRENT LIABILITIES | 532 523 | 512 899 |
| Liabilities directly associated with assets held for sale | 12 860 | – |
| TOTAL SHAREHOLDERS' EQUITY AND LIABILITIES | 2 210 283 | 2 058 566 |
| * Including short-term banking facilities | 39 390 | 21 959 |
| (in thousands of euros) | 12/31/2024 | 12/31/2023 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| NET PROFIT (LOSS) | 55 424 | 36 667 |
| Elimination of net expenses not affecting cash flows: | ||
| - Depreciation, Amortization and non-current financial provisions | 109 768 | 100 368 |
| - Changes in deferred taxes | (2 449) | 8 765 |
| - Incarne on disposals, provisions for liabilities and others | 9 811 | (11 465) |
| GROSS CASH FLOW MARGIN | 172 554 | 134 335 |
| Net changes in provisions associated with ongoing operations | (2 524) | (1 835) |
| OPERATING CASH FLOW | 170 030 | 132 499 |
| Income tax expense elimination | 23 064 | 15 318 |
| Elimination of net interest expense paid | 28 770 | 17 986 |
| Effect of changes in inventory | (29 314) | (37 605) |
| Effect of changes in accounts receivable and accounts payable | 11 027 | 25 974 |
| NET CASH PROVIDED BY OR USED FOR OPERATIONS BEFORE TAX | 203 577 | 154 173 |
| Tax paid | (16 737) | (17 256) |
| CASH PROVIDED BY OR USED FOR OPERATING ACTIVITIES (A) | 186 841 | 136 916 |
| INVESTMENT ACTIVITIES | ||
| Acquisition of consolidated companies | – | – |
| Acquired cash | – | – |
| Acquisition of tangible and intangible fixed assets | (106 801) | (98 889) |
| Acquisition of financial assets | (5 112) | (3 000) |
| Change in granted loans and advances | (287) | (67) |
| TOTAL CASH USED FOR INVESTMENT ACTIVITIES | (112 200) | (101 956) |
| Divested cash | – | – |
| Disposal of consolidated companies | – | – |
| Disposal of tangible and intangible fixed assets | 6 404 | 2 182 |
| Disposal of financial assets | – | – |
| TOTAL CASH FROM DISPOSALS | 6 404 | 2 182 |
| CASH PROVIDED BY OR USED FOR INVESTMENT ACTIVITIES (B) | (105 796) | (99 774) |
| FINANCING ACTIVITIES | ||
| Capital increase | 840 | 4 106 |
| Capital decrease (OPRA) | – | (204 552) |
| Dividends paid to Group shareholders | (14 195) | (7 996) |
| Dividends paid to minority interests of consolidated companies | – | – |
| TOTAL CASH FROM EQUITY TRANSACTIONS | (13 355) | (208 441) |
| New long-term loans | 101 700 | 267 585 |
| New short-term loans | 1 530 | 621 |
| Repayment of long-term loans | (1 814) | (23 555) |
| Repayment of short-term loans | (103 098) | (79 445) |
| Net interest expense paid | (28 770) | (17 986) |
| TOTAL CASH FROM ON LOANS AND OTHER FINANCIAL LIABILITIES | (30 453) | 147 221 |
| CASH PROVIDED BY OR USED FOR FINANCING ACTIVITIES (C) | (43 808) | (61 220) |
| Effect of change in foreign exchange rates (D) | (2 119) | 3 643 |
| Effect of adjustments in treasury shares (D) | (200) | 490 |
| CHANGES IN CASH (A+B+C+D) | 34 917 | (19 945) |
| Cash at January 1 (E) | 117 353 | 137 298 |
| Cash at year-end (A+B+C+D+E) | 152 270 | 117 353 |
| Cash and cash equivalents | 191 660 | 139 312 |
| Short-term banking facilities | (39 390) | (21 959) |
| CLOSING CASH POSITION | 152 270 | 117 353 |
| Other elements | Group s share | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Capital stock | Capital-linked | Treasury | Consolidated | Conversion | of comprehensive |
Profit for the period, |
of shareholders' |
Minority | Total shareholders' |
||
| (in thousands of euros) | premiums | shares | reserves | reserves | income | Group share | equity | interests | equity | ||
| SHAREHOLDERS' EQUITY AT JANUARY 1, 2023 |
CAPITAUX PROPRES AU 1ER JANVIER 2023 |
21 646 | 75 329 (20 135) | 941 394 | 44 061 | (3 599) | 56 960 | 1 115 656 | 2 770 | 1 118 426 | |
| Profit (loss) for the period N (a) Résultat de l'exercice N (a) | – | – | – | – | – | – | 37 533 | 37 533 | (866) | 36 667 | |
| Translation differences (b) | Écarts de conversion (b) | – | – | – | – | (8 153) | – | – | (8 153) | 160 | (7 993) |
| Payments in shares | Paiements en actions | – | – | – | 2 302 | – | – | – | 2 302 | – | 2 302 |
| Capital increase | Augmentation de capital | – | – | – | – | – | – | – | – | 4 102 | 4 102 |
| Capital decrease (OPRA) | Réduction de capital suite à l'OPRA |
(3 030) | (75 329) | – | (126 193) | – | – | – | (204 552) | – | (204 552) |
| Restatement of treasury shares Retraitement des actions | propres | – | – | 497 | 43 | – | – | – | 540 | – | 540 |
| Revaluation of net liabilities (assets) of defined benefit plans (c) |
Réévaluation du passif (de l'actif) net des régimes à prestations définies (c) |
– | – | – | – | – | (4 106) | – | (4 106) | – | (4 106) |
| Appropriation of N-1 earnings | Affectation résultat N-1 | – | – | – | 56 960 | – | – | (56 960) | – | – | – |
| Dividends distributed | Dividendes distribués | – | – | – | (7 996) | – | – | – | (7 996) | – | (7 996) |
| Restatement of financial instruments (d) |
Retraitement des instruments financiers (d) |
– | – | – | – | – | 1 150 | – | 1 150 | 5 | 1 155 |
| Various | Divers | – | – | – | 191 | – | – | – | 191 | – | 191 |
| SHAREHOLDERS' EQUITY AT DECEMBER 31, 2023 |
CAPITAUX PROPRES AU 31 DÉCEMBRE 2023 |
18 615 | – (19 638) | 866 704 | 35 908 | (6 554) | 37 533 | 932 565 | 6 171 | 938 736 | |
| including total income and expenses reported for the year (a) + (b) + (c) + (d) |
dont total des produits et charges comptabilisés au titre de la période (a) + (b) + (c) + (d) |
– | – | – | – | (8 153) | (2 955) | 37 533 | 26 425 | (701) | 25 723 |
| SHAREHOLDERS' EQUITY AT JANUARY 1ST, 2024 |
CAPITAUX PROPRES AU 1ER JANVIER 2024 |
18 615 | – (19 638) | 866 704 | 35 908 | (6 554) | 37 533 | 932 565 | 6 171 | 938 736 | |
| Profit (loss) for the period N (a) Résultat de l'exercice N (a) | – | – | – | – | – | – | 56 006 | 56 006 | (582) | 55 424 | |
| Translation differences (b) | Écarts de conversion (b) | – | – | – | – | 23 727 | – | – | 23 727 | 146 | 23 873 |
| Payments in shares | Paiements en actions | – | – | – | 1 871 | – | – | – | 1 871 | – | 1 871 |
| Capital increase | Augmentation de capital | – | – | – | – | – | – | – | – | 837 | 837 |
| Capital decrease (OPRA) | Réduction de capital suite à l'OPRA |
– | – | – | – | – | – | – | – | – | – |
| Restatement of treasury shares Retraitement des actions | propres | – | – | (442) | (80) | – | – | – | (522) | – | (522) |
| Revaluation of net liabilities (assets) of defined benefit plans (c) |
Réévaluation du passif (de l'actif) net des régimes à prestations définies (c) |
– | – | – | – | – | 1 371 | – | 1 371 | – | 1 371 |
| Appropriation of N-1 earnings | Affectation résultat N-1 | – | – | – | 37 533 | – | – | (37 533) | – | – | – |
| Dividends distributed | Dividendes distribués | – | – | – | (14 195) | – | – | – | (14 195) | – | (14 195) |
| Restatement of financial instruments (d) |
Retraitement des instruments financiers (d) |
– | – | – | – | – | (1 111) | – | (1 111) | (5) | (1 117) |
| Various | Divers | – | – | – | (79) | – | – | – | (79) | – | (79) |
| SHAREHOLDERS' EQUITY AT DECEMBER 31, 2024 |
CAPITAUX PROPRES AU 31 DÉCEMBRE 2024 |
18 616 | – (20 080) | 891 754 | 59 635 | (6 295) | 56 006 | 999 633 | 6 567 | 1 006 200 | |
| including total income and expenses reported for the year (a) + (b) + (c) + (d) |
dont total des produits et charges comptabilisés au titre de la période (a) + (b) + (c) + (d) |
– | – | – | – | 23 727 | 260 | 56 006 | 79 993 | (441) | 79 552 |
Have a question? We'll get back to you promptly.